Navigation Links
Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
Date:2/19/2008

BRISTOL, Tenn., Feb. 19 /PRNewswire/ -- Graceway Pharmaceuticals, LLC ("Graceway"), a portfolio company of GTCR Golder Rauner, LLC, announced today that it has acquired all of the assets related to Estrasorb(R) (estradiol topical emulsion) in North America from Novavax, Inc. ("Novavax") (Nasdaq: NVAX) and Allergan, Inc. ("Allergan") (NYSE: AGN). Estrasorb is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and is available by prescription only.

The agreements between Novavax and Graceway provide for the sale by Novavax of the patent associated with the product, the sale of other intellectual properties (including trademarks, copyrights, know-how and related assets), and the sale of all production and packaging equipment related to Estrasorb. Graceway will license back to Novavax rights to its micellar nanoparticle technology for application in fields unrelated to Estrasorb. The license is free of royalties. Novavax and Graceway have also executed a supply agreement under which Novavax will manufacture additional finished goods of Estrasorb for a limited period.

In a separate but related transaction, Graceway has also purchased from Allergan the New Drug Application for the Estrasorb product, raw material and finished goods inventories, and any tangible and intangible assets related to the product. Simultaneous with the transaction between Novavax and Graceway, Allergan has terminated all of its previously licensed rights to commercialize the product. Following the transaction, Allergan will have no continuing role with the product. All rights to make or have made, develop, commercialize and sell the Estrasorb product in North America are now held by Graceway.

About Graceway Pharmaceuticals, LLC

Graceway Pharmaceuticals, LLC ("Graceway"), headquartered in Bristol, Tennessee, is a pharmaceutical company focused on acquiring, in-licensing, and developing branded prescription pharmaceutical products. Current prescription products marketed by Graceway include Aldara(R) (imiquimod) Cream 5%, Maxair(R) Autohaler(R) (pirbuterol acetate inhalation aerosol), Atopiclair(R) Nonsteroidal Cream, and Benziq(R)(benzoyl peroxide). Aldara, Maxair, Autohaler, and Tambocor are trademarks owned by or licensed to Graceway.

About GTCR Golder Rauner, LLC

Founded in 1980, GTCR Golder Rauner, LLC ("GTCR") is a leading private equity investment firm and long-term strategic partner for outstanding management teams. The Chicago-based firm pioneered the investment strategy of identifying and partnering with exceptional executives to acquire and build companies through a combination of acquisitions and strong internal growth. GTCR currently manages more than $8 billion of equity capital invested in a wide range of companies and industries. More information about GTCR may be found at http://www.gtcr.com.

Contact:

Graceway Pharmaceuticals, LLC:

John Bellamy

Executive Vice President & General Counsel

(423) 274-2100

Russo Partners, LLC:

Wendy Lau

(212) 845-4272


'/>"/>
SOURCE Graceway Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
2. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
3. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
4. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
5. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... Triangle Park, North Carolina (PRWEB) , ... November 30, 2016 , ... ... (IUPAC) approved the names and symbols for four elements: nihonium (Nh), moscovium (Mc), ... Following a 5-month period of public review, the names earlier proposed by the discoverers ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
Breaking Biology News(10 mins):